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Baracaldo, SpainObjective: To evaluate the influence on sperm parameters and in vitro fertilization (IVF) outcomes of the administration of 400 mg/day
of vitamin E for 3 months to men from infertile couples who are undergoing IVF.
Design: Double-blind, placebo-controlled, randomized study.
Setting: Human reproduction unit of a university hospital.
Patient(s): A total of 101 couples, 50 in the vitamin E group and 51 in the placebo group, undergoing IVF, among whom 64.4% of cases
had an abnormal spermiogram according to World Health Organization (WHO) criteria.
Intervention(s): Vitamin E (a-tocopherol), 400 mg daily by mouth for 3 months, with sperm analysis performed immediately before
starting the treatment and 3 months later on the day of IVF.
Main Outcome Measure(s): WHO sperm parameters and IVF outcomes.
Result(s): Although there was a statistically significant increase in progressive motility in the vitamin E group compared with before-
treatment values, a similar increase occurred in the placebo group. Normal morphology was even better in the placebo group. Regarding
IVF outcomes, better fertilization rates were observed in the placebo group, but the live-birth rate per transfer was statistically
significantly higher in the vitamin E group: 17 (41.46%) of 41 versus 9 (20.46%) of 44 in the placebo group. Although the clinical
pregnancy rates (both per transfer and per cycle started) and the implantation rate were somewhat higher in the vitamin E group
(43.9% and 25%; 36.0% and 22.0%; and 24.7% and 14.1%, respectively), the increase was not statistically significant.
Conclusion(s): The effect of vitamin E on classic sperm parameters was not an improvement over placebo. Nonetheless, vitamin E
administration was associated with a statistically significantly higher live-birth rate, and there was a trend toward better results in
other IVF parameters.
Clinical Trial Registration Number: Eudra CT 2007-000960-25. (Fertil Steril Rep 2020;1:219–26. 2020 by American Society for
Reproductive Medicine.)
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ORIGINAL ARTICLE: FEATURED ARTICLESbe the cause of decline in sperm quality (6). Human sperma-
tozoa are redox active cells capable of generating the small
amount of ROS that are needed for sperm maturation, capac-
itation, hyperactivation, and acrosome reaction as well as
sperm–oocyte fusion (7). However, excessive production of
ROS results in DNA damage, reduces motility, negatively af-
fects membrane integrity, and reduces sperm–oocyte fusion
ability (7, 8).
To counteract OS, seminal plasma and spermatozoa
themselves have a number of antioxidant systems and sub-
stances, among them vitamin E (9–11). It has been suggested
that antioxidants be used to treat male infertility.
Nonetheless, there could be some concern because an
excess of antioxidants might not be beneficial because an
adequate balance between oxidative and antioxidative
systems is needed for optimal performance of biological
functions (12, 13).
Previous studies on antioxidant treatment of male factor
infertility are very heterogeneous in terms of population char-
acteristics (normal population, infertile men, men who are
participating in in vitro fertilization [IVF]), the antioxidant(s)
employed, and the concomitant therapies (IVF, intrauterine
insemination, ovarian stimulation, natural intercourse). In a
meta-analysis performed in 2019, which included data from
the work we report here (which was in process at the time),
61 randomized studies were included (6,264 subfertile males).
It was concluded that antioxidant supplementation in subfer-
tile males may improve live-birth rates for couples attending
fertility clinics (14).
One of the best-known antioxidants is vitamin E. This
vitamin has eight isoforms. Of them, a-tocopherol has the
highest in vivo bioactivity and is the only one that is essential
in humans. It is considered the most important lipophilic anti-
oxidant in vivo—in humans in particular—metabolizing per-
oxyl radicals (15, 16). Given these characteristics, it has
employed for treating and/or preventing various conditions
(16).
Several points should be highlighted first. [1] The assess-
ment of OS is complex and many different ROS and antioxi-
dant systems could be analyzed (17, 18). [2] There is currently
no consensus concerning the best method to measure OS in
clinical settings (19). [3] In menwith normal semen character-
istics who are part of couples experiencing unexplained infer-
tility, the role of OS is not well defined (19). [4] There is
controversy concerning the relationship of some OS markers
with sperm parameters in assisted reproduction technology
(ART) (20). [5] Oxidative stress may be circumvented by
ART (20). In this context, our study with couples undergoing
IVF and intracytoplasmic sperm injection (ICSI) assessed
whether vitamin E treatment of men—regardless of their diag-
nosis—could increase pregnancy rates.MATERIALS AND METHODS
Population
For a 2-year period (from March 2012 to June 2014), couples
presenting at the reproduction unit of our university hospital
to undergo IVF-ICSI treatment were invited to participate in
our study. The inclusion criteria were [1] woman’s age of22018–40 years; [2] infertility duration >2 years; [3] fewer
than two previous IVF-ICSI cycles; [4] antral follicle count
of >6 and/or antim€ullerian hormone level of >0.4 ng/mL;
[5] no contraindications to IVF or pregnancy; [6] no use of
donor sperm; [7] use of own fresh oocytes; [8] woman’s
body mass index (BMI)<36 kg/m2 because this is the general
criterion for inclusion in our public health system; [9] absence
of uterine abnormalities or hydrosalpinges; [10] man’s age of
18–50 years; and [11] man’s BMI <45 kg/m2. The exclusion
criteria were [1] certain conditions in the man (endocrinologic
or cardiovascular conditions, oncologic infective condition,
or psychiatric disorders), [2] illicit drug use, [3] azoospermia,
[4] abnormal karyotype, [5] preimplantational genetic diag-
nosis cycles, [6] donor oocyte cycles, and [7] testicular biopsy
cycles.Study design
Once the indication for IVF-ICSI had been established based
on sperm analysis, medical records, and ancillary tests, cou-
ples were invited to participate in the study. If the couples
agreed and gave written informed consent, they were ran-
domized into one to two groups: [1] a vitamin E group or
[2] a placebo group. The groups began to take either vitamin
E (a-tocopherol) at 400 mg/day or identical placebo capsules
from 3 months before the expected date of oocyte pickup
(OPU). The vitamin treatment was started 90 days before the
scheduled day of OPU because the spermatogenesis cycle
takes approximately 72 days (21).
Randomization was performed using a sealed opaque en-
velope system. The study was double-blinded (for couples and
the team of clinicians and biologists involved in the research).
The blind was not broken until the completion of the study.
This study was approved by Cruces Hospital’s institutional re-
view board (CEIC-07/17) and was registered in Eudra CT (ref.
2007–000960–25). It was partially funded by a public grant
from the Health Department of the Basque Country and
received no funding from pharmaceutical companies.Sample size calculation
The main objective was to ascertain an increase in the sperm
concentration. Accepting an alpha risk of 0.05 and a beta risk
of 0.2 in a two-sided test, 102 couples (51 in each group) were
required to detect a difference greater than or equal to 10
million spermatozoa/mL as statistically significant. The com-
mon standard deviation was assumed to be 18 million sper-
matozoa/mL (based on our previous data) and the dropout
rate 0. The secondary outcomes were the remaining WHO
sperm parameters as well as IVF outcomes (fertilization, im-
plantation, and pregnancy rates), total pregnancy rates
(including natural cycle conceptions), and adverse effects.Patient selection
Among the 160 couples assessed for eligibility, 113 met selec-
tion criteria for enrollment in this study. Of these, 55 were
randomized to vitamin E and 58 to placebo. The main demo-
graphic characteristics of the population included are summa-
rized in Table 1. The most common indications for IVF wereVOL. 1 NO. 3 / DECEMBER 2020
TABLE 1
Population characteristics before starting treatment (vitamin E or placebo) in patients eventually undergoing in vitro fertilization.
Characteristic
Study group
P valuePlacebo (n [ 51) Vitamin E (n [ 50)
Man’s age (y) 37.2  3.8 37.8  3.3 .449
Woman’ age (y) 35.9  2.2 35.2  2.7 .310
Woman >35 y (%) 56.9 (29/51) 52 (26/50) .6914
Man smoking (%) 23.5 (12/51) 28.0 (14/50) .692
Woman smoking (%) 41.2 (21/51) 40.0 (20/50) .9042
First IVF cycle (%) 50.98 (26/51) 48.0 (24/50) .8431
Main IVF indications (%)a
Male infertility 60.8 (31/51) 68 (34/50) .449
Idiopathic infertility 23.5 (12/51) 20 (10/50) .6675
Tubal factor 11.8 (6/51) 8 (4/50) .5265
Endometriosis 9.8 (5/51) 8 (4/50) .7504
Main male diagnosis (%)
Normozoospermia 39.2 (20/51) 32 (16/50) .449
Oligozoospermia 9.8 (5/51) 24 (12/50) .05659
Asthenozoospermia 15.7 (8/51) 8 (4/50) .2326
Teratozoospermia 35.3 (18/51) 36 (18/50) .941
Days of abstinence 3.6  1.3 3.6  1.7 .452
Median (min–max) 3 (1–6) 3 (1–7)
Semen volume (mL) 3.3  1.6 3.2  1.4 .750
Median (min–max) 2 (1–8) 3 (1–8)
Total sperm count (millions) 186.3  168.3 185.8  167.5 .7988
Median (min–max) 135 (5–600) 150 (1–570)
Concentration (106/mL) 60  37.3 59.5  42.3 .7274
Median (min–max) 50 (2–120) 60 (1–120)
Motility grade AþB (%) 49.7  14.5 52.5  14.8 .4090
Median (min–max) 55 (15–70) 56 (20–75)
Normal morphology (%) 3.8  2.3 3.7  2.6 .7033
Median (min–max) 4 (0–10) 3 (0–10)
Note: Values are mean  standard deviation unless otherwise indicated. IVF ¼ in vitro fertilization.
a Totaling >100%.
Matorras. Vitamin E administration and ART outcome. Fertil Steril Rep 2020.
Fertil Steril Rep®male factor infertility (65.5 %), tubal factor infertility (13.5%),
endometriosis (8.8 %), and idiopathic infertility (22.1%). The
most common sperm diagnoses were normozoospermia
(34.5%), oligozoospermia (15.9), asthenozoospermia
(12.4%), and teratozoospermia (33.6%).
Semen analysis was performed after 4 days of sexual
abstinence. The patients collected a semen sample by mastur-
bation into sterile containers at the hospital, and the samples
were analyzed within 1 hour of ejaculation. After liquefaction
of the semen at room temperature (22C) for 30 minutes, ejac-
ulate analysis was performed in accordance with the 2010
WHO criteria (22), which included the assessment of semen
volume, and sperm concentration, and morphology.
Sperm concentration was measured using a hemocytom-
eter (Improved Neubauer; Hauser Scientific). Briefly, 10 mL of
well-mixed semen was placed on a clean glass slide that had
been stored at 37C and covered with a 22 22 mm coverslip.
The preparation was placed on the heating stage of a micro-
scope at 37C and was immediately examined at 400
magnification. The same specialized biologist (P-S, J) per-
formed all the semen analyses.
The patients were categorized according to the 2010WHO
criteria into the following categories: normozoospermia, oli-
gozoospermia, asthenozoospermia, or teratozoospermia (22).
In cases with more than one abnormal sperm parameter, theVOL. 1 NO. 3 / DECEMBER 2020most severe was considered for classification purposes. For
this study, sperm analysis was performed on two occasions:
[1] immediately before starting treatment (vitamin or pla-
cebo); and [2] 3 months later, on the same day as IVF, with
an aliquot of the sample used for IVF-ICSI.IVF methodology
Our IVF management has been described elsewhere (23, 24).
Briefly, it consists of down-regulation with the
gonadotropin-releasing hormone analogue triptorelin acetate
(Decapeptyl; Ipsen) on a long protocol, ovarian stimulation;
[1] women %35 years received only recombinant follicle-
stimulating hormone (FSH) (Gonal F, Merck Serono), and [2]
women >35 years received recombinant FSH, and highly pu-
rified urinary menopausal gonadotropins (Menopur, Ferring)
or recombinant FSH and recombinant luteinizing hormone
(Pergoveris; Merck Serono). Ovulation was triggered with
250 mg of Ovitrelle (Merck). We scheduled OPU 36 hours after
the human chorionic gonadotropin injection, and the luteal
phase was supplemented with micronized progesterone (Utro-
gestan; Laboratorios Seid), 200 mg vaginally/12 hours. Dur-
ing the study period, no ovarian triggering was performed
with gonadotropin-releasing hormone agonists, and cycles
with hyperstimulation risk were canceled.221
ORIGINAL ARTICLE: FEATURED ARTICLESImplantation rate was defined as the number of embryos
transferred that developed to the stage of a gestational sac on
ultrasound divided by the total number of embryos trans-
ferred. Clinical pregnancy was defined as an intrauterine
gestational sac on ultrasound with fetal heart activity at 7–
8 weeks of gestation. Live birth was defined as the birth of
a viable infant born after 24 weeks of gestation, and twins
delivered by one mother were counted as one live birth.
Global live-birth rate was defined as the sum of live births re-
sulting from IVF transfers and those resulting from natural
intercourse during the treatment period (with placebo or
vitamin E) divided by the total number of couples in each
treatment group.Statistical evaluation
All variables were checked for normal distribution by
applying the Kolmogorov-Smirnov one-sample test for
goodness-of-fit. Factorial analysis of variance (ANOVA) for
repeated measurements was performed for testing statistically
significant differences between the study groups. Two-sided
P< .05 was considered statistically significant. Confidence in-
tervals for differences in sperm motility before and during
treatment were calculated from the binomial distribution.
Values determined before and after treatment were compared
with the paired t-test. Qualitative parameters were studied
with the chi-square test as well as odds ratio (OR) and 95%
confidence interval (CI). Computations were performed using
SPSS (version 22; IBM).RESULTS
Study flow chart
A total of 160 couples were contacted, and of these, 113
(89.4%) were enrolled in the study. Three natural cycle preg-
nancies were achieved during the study period, at 45, 50, and
70 days of treatment. After breaking the study blinding, we
found that two were in the placebo group and the other in
the vitamin E group. For various reasons, nine other couples
eventually did not perform IVF in this study: five in the pla-
cebo group (three cycles canceled due to low response and two
due to hyperresponse) and four in the vitamin E group (two for
low response and two for hyperresponse). Therefore, in the
end 101 couples were included in the study: 50 men received
vitamin E, and 51 received placebo (Fig. 1). No after-
treatment sperm analysis was performed in cases of preg-
nancy or canceled cycles. The main demographic and clinical
characteristics of the population who eventually underwent
IVF are summarized in Supplemental Table 1 (available
online).Baseline sperm characteristics in vitamin E and
placebo groups
As expected in a randomized trial, the main demographic
characteristics and sperm parameters were similar in the
two groups (Table 1), as were the main IVF indications.222Sperm parameters before and after 3 months of
treatment (with vitamin E or placebo) in the entire
population
Sperm concentration (74.45 million/mL  40.06) statistically
significantly increased from the day immediately before start-
ing treatment to the day of IVF (59.75 39.85, P¼ .01). Simi-
larly, progressive motility statistically significantly increased
(70.6%  33.9 vs. 51.1 14.65, P< .001) (Table 2). Total
motile sperm count almost doubled (83.4  87.2 million vs.
156.4  141.4 million, P¼ .001). There were no statistically
significant changes in total spermatozoa or normal
morphology.Sperm parameters before and after 3 months
treatment considered separately in the vitamin E
and in the placebo group
In the vitamin E group, the progressive motility statistically
significantly increased (52.5%  14.8 vs. 72.3  41.6)
(P¼ .001) (Table 2). The total motile sperm count almost
doubled (86.9  90.1 million vs. 160.7  155.6 million,
P¼ .025). The total sperm count and sperm concentration,
although somewhat higher, did not statistically significantly
change. There were no changes in the percentage of normal
morphology.
In the placebo group, there were statistically significant
increases in sperm concentration (60  37.3 million/mL vs.
76.7  39.6 million/mL), progressive motility (49.7% 
14.5% vs. 70.9%  22.6%) and also normal morphology
(3.8%  2.3% vs. 5.1%  3.5%). The total motile sperm
count almost doubled (79.9  84.9 vs. 152.1  127.5,
P¼ .001). There were no differences concerning total sperm
count. In comparing the sperm parameters between the
groups after 3 months of treatment, the results were found
to be similar except the percentage of normal forms, which
was statistically significantly higher in the placebo group
than in the vitamin E group (5.1%  3.5% vs. 3.7% 
2.4%, P¼ .04).
Exploring the different sperm diagnosis categories,
similar patterns were observed. In the normozoospermia
group, the sperm concentration increased from 60  31.3
million/mL to 77.9  36.9 million/mL in the placebo group
(P¼ .055) and from 69.3  30.5 million/mL to 92.2  35.1
million/mL in the vitamin E group (P¼ .07). In the group
where the main diagnosis was teratozoospermia, the percent-
age of normal forms increased from 2.1%  0.7% to 4.7% 
1.1% in the placebo group (P¼ .001) and from 1.8% 0.8% to
3.0% 1.6% in the vitamin E group (P¼ .03). When the main
diagnosis was asthenozoospermia, the percentage of sperma-
tozoa with progressive motility grew from 24.3%  6.2% to
35.8%  11.5% in the placebo group (P¼ .15) and from
26.2%  6.3% to 37.9%  12.4% in the vitamin E group
(P¼ .10). Finally, in the oligozoospermia group the sperm con-
centration increased from 4.8  4.6 million/mL to 6.8  5.6
million/mL in the placebo group (P¼ .55) and from 6.3 
3.9 million/mL to 8.4 6.1 million/mL in the vitamin E group
(P¼ .49) (n ¼ 12).VOL. 1 NO. 3 / DECEMBER 2020
FIGURE 1
Flow chart of participants from recruitment to analysis of effect of antioxidant therapy.
Matorras. Vitamin E administration and ART outcome. Fertil Steril Rep 2020.
Fertil Steril Rep®IVF results
The mean age of the woman, the number of oocytes ob-
tained, and the percentage of cycles undergoing ICSI were
very similar in the two groups (Table 3). The fertilization
rate in the vitamin E group was 54.80%  28.6%, statisti-
cally significantly lower than the rate of 66.5%  29.1%
in the placebo group (P¼ .022). When the fertilization rate
was considered separately for couples receiving ICSI or
IVF, the results were somewhat higher in placebo group,
but statistical significance was not reached (67.2% 
30.3% vs. 55.6%  32.7% in ICSI , P¼ .052 and 64.1% 
27.4% vs. 52.4%  25.5% in IVF, P¼ .069). Nonetheless,
the mean number of oocytes fertilized was similar in the
two groups (5.0  4.3 vitamin E group vs. 5.4  4.1 placebo
group). The percentage of couples with at least one high-VOL. 1 NO. 3 / DECEMBER 2020quality embryo and the number of embryos transferred
were also similar in the two groups.
In the vitamin E group, there was a trend toward a higher
clinical pregnancy rate per transfer (43.9% vs. 25.0%), preg-
nancy rate per cycle started (36% vs. 22%), and implantation
rate (24.7% vs. 14.1%), but the differences did not reach sta-
tistical significance. The corresponding ORs were 2.34 (95%
CI, 0.94–5.89), 2.05 (95% CI, 0.85–4.94), and 1.94 (95% CI,
0.92–4.06), respectively.
The live-birth rate per transfer was statistically signifi-
cantly higher in the vitamin E group (41.46% vs. 20.46% in
the placebo group, P¼ .04; OR 2.75; 95% CI, 1.05–7.19). The
live-birth rate per cycle started and global live-birth rate
were somewhat higher in the vitamin E group, though the dif-

















































































































































































































































































































































































































































































































































































































































































































































































































































ORIGINAL ARTICLE: FEATURED ARTICLESAdverse effects and costs
Oral administration of vitamin E was well tolerated, and no
adverse effects or laboratory abnormalities were observed.
The cost of the complete vitamin E treatment per patient,
based on Spanish market prices, would be 10,53 euro (3.51
euro per month for 30 capsules of 400 mg of vitamin E multi-
plied by 3 for the 3-month treatment).DISCUSSION
Oxidative stress is recognized to be a major cause of male
infertility (6). Nonetheless, there is no agreement concerning
the best method to assess it or the cutoff points of normality.
Many different antioxidants have been proposed, alone or in
combination, in different clinical settings. The results,
although controversial, have suggested a beneficial effect of
antioxidants (14). On the other hand, the beneficial effect, if
any, of antioxidants on normal sperm is unknown. Therefore,
we directed our study to our general IVF population, in which
the rate of abnormal sperm is nearly 65% following WHO
criteria.
We selected vitamin E as the antioxidant based on previ-
ous data in the literature on male fertility (25–27), as well as
its safety profile (16, 28) and price. Vitamin E is a collective
term that describes eight naturally occurring homologues
with potent antioxidant properties. All eight homologues
are differentially distributed within food sources (29), but a-
tocopherol is the only form that is recognized to meet
human requirements (16). The recommended dietary
allowance for a-tocopherol is currently 15 mg/day in adults
with a recommended upper intake level of 1,000 mg/day for
supplemental vitamin E (28).
One interesting finding in our study is that after 3 months
of treatment there were notable improvements in many sperm
parameters, regardless of whether the man had received
vitamin E or placebo. In our opinion, the explanation could
be the well-known Hawthorne effect. This effect was first
described when it was observed in a population of workers
that their work productivity increased regardless of the
changes made due to the psychological stimulus of being
singled out and made to feel important (30). It could be spec-
ulated that the men in our study adopted healthier habits
(concerning exercise, diet, smoking, and alcohol consumption
or other drugs) and that these changes led to improvements in
sperm characteristics. This could also be responsible for the
non-negligible natural cycle pregnancy rate (nearly 1% per
month). This underlines the great importance of double-
blind protocols in studies focusing on male fertility.
The results of previous studies on the effect of vitamin E
on sperm parameters have been controversial (10, 25, 31). As
for the composition of the vitamin E group there was a higher
proportion of oligozoospermia, close to statistical signifi-
cance. One could speculate that this might have influenced
the results. In our study, it should also be highlighted that
some of the changes were similar in the placebo and vitamin
E groups. There was a marked, statistically significant in-
crease in progressive motility in both groups. Sperm concen-
tration also increased in both groups, although the change
only reached statistical significance in the placebo group.VOL. 1 NO. 3 / DECEMBER 2020
TABLE 3





(n [50) OR (95% CI) P value
Intention to treat 58 55
Woman’s age (y) 35.9  2.2 35.2  2.7 .310
Total no. of oocytes retrieved 11.0  6.7 11.2  7.1 .992
ICSI (%) 78.4 (40/51) 76 (38/50) .82
Fertilization rate (%) 66.5  29.1 54.8  28.6 .022
No. of oocytes fertilized 5.4  4.1 5.0  4.3 .429
Patients with at least 1 top-
quality embryo on day 3 (%)
55.0 (28/51) 46.0 (23/50) .273
No. of embryos transferred 2.0  0.9 1.9  1.0 .766
CPR per transfer (%) 25.0 (11/44) 43.9 (18/41) 2.34 (0.94–5.89) .069
CPR per cycle started (%) 22.0 (11/51) 36.0 (18/50) 2.05 (0.85–4.94) .11
Implantation rate (%) 14.1 (14/99) 24.7 (22/91) 1.94 (0.92–4.06 .08
LBR per transfer (%) 20.46 (9/44) 41.46 (17/41) 2.75 (1.05–7.19) .04
LBR per cycle started (%) 17.62 (9/51) 34.0 (17/50) 2.4 (0.95–6.07) .06
Global LBR (%) 18.9 (11/58) 32.7 (18/55) 2.08 (0.88–4.93) .097
Note: Values are expressed as mean  standard deviation, unless indicated otherwise. CI ¼ confidence interval; CPR ¼ clinical pregnancy rate; ICSI ¼ intracytoplasmic sperm injection; LBR ¼ live-
birth rate; OR ¼ odds ratio.
Matorras. Vitamin E administration and ART outcome. Fertil Steril Rep 2020.
Fertil Steril Rep®Finally, the percentage of normal forms only statistically
significantly increased in the placebo group. With the specific
sperm categories, similar patterns were observed although in
some categories the statistical analysis was hampered by the
small sample size of the subgroups. Although the separate
analysis found no statistically significant differences, it
should be remembered that the study was not powered to
analyze these subgroups. Our results are consistent with those
of a recent randomized trial in which antioxidants did not
improve sperm parameters among men with male factor
infertility (32).
Regarding IVF outcomes, our results are paradoxical. On
the one hand, in agreement with the aforementioned better
sperm parameters in the placebo group, the fertilization rate
was statistically significantly higher in the placebo group.
Nonetheless, the live-birth rate per transfer was statistically
significantly higher in the vitamin E group (41.46% vs.
20.46% placebo group, P¼ .04; OR 2.75; 95% CI, 1.05–7.19).
In all the other IVF outcome parameters considered (implan-
tation rate and clinical pregnancy rate both per transfer and
per cycle started, live-birth rate per cycle started, and global
live-birth rate), the ORs were nearly 2 in favor of vitamin E,
but the trends did not reach statistical significance.
It has been highlighted that vitamin E does not simply
have an antioxidant effect. Specifically, the reported nonan-
tioxidant effects of vitamin E involve the modulation of
cellular responses including survival, inflammation, cellular
adhesion, migration, secretion, and immunity either by
modulating enzymes in signal transduction pathways (espe-
cially protein kinase) or regulating activities of specific tran-
scription factors (16, 33–36). It could be speculated that, by
some of the aforementioned mechanisms, vitamin E–treated
spermatozoa have a somewhat impaired fertilization ability,
but this resulted in better embryo quality. Our relatively small
sample size meant that we were unable to investigate the ef-
fects on IVF in each male diagnosis subgroup. More studies
are needed to confirm our results, especially in relation toVOL. 1 NO. 3 / DECEMBER 2020male diagnosis and OS status. Our work opens the door to
different lines of research to investigate the influence of
vitamin E on the spermatozoa, such as sperm DNA fragmen-
tation and markers of OS in the seminal plasma and in the
spermatozoa membranes.CONCLUSION
The effect of vitamin E on classic sperm parameters is not bet-
ter than that of placebo. Nonetheless, we found vitamin E
administration was associated with a statistically signifi-
cantly higher live-birth rate, and there was a trend toward
better results in other IVF parameters.REFERENCES
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